**Core tip:** A preoperative systemic immune-inflammation index based on peripheral lymphocyte, neutrophil, and platelet counts was established, and better prognostic predictive abilities for overall survival and recurrence were found when compared with neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with colorectal cancer. This index might assist the identification of high-risk patients among patients with the same TNM stage in clinical practice.

INTRODUCTION
============

Colorectal cancer (CRC), the third most frequently diagnosed cancer in men, and the second in women, is the third most common cause of cancer-related mortality worldwide\[[@B1]\]. The incidence of CRC in the United States has decreased owing to the improvements in cancer screening and the removal of precancerous adenomas\[[@B2]\]. However, an increase in the incidence of CRC was observed in many developing countries\[[@B3]\]. Owing to the absence of early symptoms and a hesitation in performing colonoscopy, a considerable number of CRC patients are diagnosed at an advanced stage, with an unfavorable overall survival (OS)\[[@B4]\]. Currently, the TNM staging system for CRC is the most commonly used predictor of OS and recurrence. However, prognostic heterogeneity was observed among patients with the same TNM stage\[[@B5]\], which causes confusion among clinicians when making therapeutic choices. Hence, more potential biomarkers should be included in clinical practice to improve prognostic prediction.

The interplay between systemic inflammation and the local immune response was recognized as the seventh hallmark of cancer, and it has been demonstrated to be involved in the initiation, development, and progression of several types of malignancies\[[@B6],[@B7]\]. Cancer-related inflammation encompasses tumor-derived and host-derived cytokines, immune cells, and small inflammatory protein mediators\[[@B8],[@B9]\], and is determined by the levels of serum leukocytes, neutrophils, lymphocytes, platelets, and acute-phase proteins such as C-reactive protein. Recently, the combinations of these systemic inflammation parameters, including neutrophil-lymphocyte ratio (NLR)\[[@B10]\] and platelet-lymphocyte ratio (PLR)\[[@B11]\], were reported as prognostic factors in some malignant solid tumors, including CRC. However, Hu et al\[[@B12]\] reported that systemic immune-inflammation index (SII), an integrated indicator based on peripheral lymphocyte, neutrophil, and platelet counts, was a powerful prognostic marker for patients with hepatocellular carcinoma. However, the SII for CRC has not been reported to date, and little is known about its prognostic value for CRC.

The aim of the present study was to investigate and compare the clinical significance and prognostic value of NLR, PLR, and SII in patients with CRC who underwent radical surgery.

MATERIALS AND METHODS
=====================

Ethics statement
----------------

The present study was approved by the ethics committee of the First Affiliated Hospital of Sun Yat-sen University. The requirement for informed consent was waived owing to the retrospective nature of this study.

Patients
--------

We retrospectively analyzed the patients with primary CRC who underwent radical surgery at the Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat-sen University between January 1994 and December 2010. 5-fluorouracil (5-FU)-based adjuvant chemotherapy was administered to stage III/IV patients and high-risk stage II patients. The inclusion criteria for patient enrollment were as follows: (1) primary colorectal adenocarcinoma confirmed by histopathology; (2) patients who underwent radical surgery; and (3) the availability of complete peripheral blood counts and follow-up data. The exclusion criteria were as follows: (1) clinical evidence of infection; (2) the presence of hematological system diseases; (3) previous treatment with neoadjuvant chemotherapy or radiochemotherapy; (4) bowel obstruction or enterobrosis resulting in emergency surgery; (5) concurrent cancers or CRC recurrence; and (6) the use of anti-inflammatory or immunosuppressive medicines. Finally, 1383 cases were enrolled in the present study.

Data collection
---------------

The following variables were analyzed: demographics (age and sex), clinicopathological features (tumor location, tumor size, histological type, and tumor stage), and treatment with chemotherapy. We defined cecum carcinoma, ascending colon cancer, and right-half transverse colon as right-sided CRC, whereas the rest were classified as left-sided CRCs. The well and moderately differentiated adenocarcinomas were histologically categorized as the well-differentiated type, and the poorly differentiated adenocarcinomas included poorly differentiated adenocarcinoma, mucinous adenocarcinoma, signet ring cell cancer, and undifferentiated cancer. Tumor staging was performed according to the 7^th^ edition of the Union for International Cancer Control-American Joint Committee on cancer classification for CRC.

Preoperative blood sampling was performed to measure the neutrophil, lymphocyte, and platelet levels for the calculation of the NLR, PLR, and SII indices. NLR and PLR were defined as the total number of neutrophils or platelets divided by the total number of lymphocytes. SII was calculated with the formula SII = (P × N)/L, where P, N, and L refer to peripheral platelet, neutrophil, and lymphocyte counts, respectively.

Follow-up
---------

Patients were followed every 3 mo in the first 2 years following surgery, every 6 mo in years 3-5, and annually thereafter. As previously described\[[@B13]\], clinical history was taken, physical examination was performed, peripheral tumor biomarker levels were measured, and chest radiography, abdominal and pelvic computed tomography or ultrasonography, and colonoscopy were performed in the follow-up period according to the NCCN Clinical Practice Guidelines in Oncology. The OS and disease-free survival (DFS) were defined as the interval between surgery and time of death or the time from the last follow-up to the time of first confirmed recurrence, respectively.

Statistical analysis
--------------------

Data was analyzed using the SPSS statistical software for Windows, version 17 (SPSS Inc., Chicago, United States). Receiver operating characteristic (ROC) curve analysis was performed to analyze the area under the ROC curve (AUC), and the Youden Index was used to identify the optimal cut-off values for NLR, PLR, and SII. Pearson *χ*^2^ test or Fisher exact test were performed to compare the different categorical variable groups. Survival analysis was performed using the Kaplan-Meier method and the Log-Rank test was used to compare the survival differences. Univariate and multivariate analyses were performed with the Cox proportional hazards regression model. A *P* value \< 0.05 was considered statistically significant.

RESULTS
=======

ROC analysis
------------

Using cancer-specific death as the end point, ROC analysis was performed to identify the optimal cut-off point with the highest sensitivity and specificity, which was 2.7 for NLR, 210 for PLR, and 340 for SII (sensitivity and specificity: 0.414 and 0.750 for NLR, 0.425 and 0.708 for PLR, and 0.857 and 0.524 for SII, respectively). For each immune-inflammation index, patients were divided into two groups for further analysis \[NLR ≤ 2.7 (low) and NLR \> 2.7 (high); PLR ≤ 210 (low) and PLR \> 210 (high); SII ≤ 340 (low) and SII \> 340 (high)\].

Baseline characteristics of patients
------------------------------------

In total, 1383 cases were enrolled in the present study. Patients in the high NLR group were more elderly compared to the low NLR group (\> 60 years old: 54.7% *vs* 46.8%, respectively); however, associations between age and the levels of PLR and SII were not identified. Moreover, there were significant sex distribution differences in the three groups. In addition, cases in the high NLR and PLR groups were more likely to have left-sided CRC; however, the tumor location did not differ significantly between the high and low SII groups. High levels of NLR, PLR, and SII correlated with poor histological differentiation, larger tumor size, advanced T stage, N stage, M stage, TNM stage, and chemotherapy. The associations of NLR, PLR, and SII with clinicopathological parameters are demonstrated in Table [1](#T1){ref-type="table"}.

###### 

Baseline patient characteristics based on neutrophil-lymphocyte ratio, platelet-lymphocyte ratio and systemic immune-inflammation index *n* (%)

                          **Cases**     **NLR**      ***P* value**   **PLR**    ***P* value**   **SII**      ***P* value**                             
  ----------------------- ------------- ------------ --------------- ---------- --------------- ------------ --------------- ------------ ------------ ----------
  Age (yr)                                                           0.005                                   0.904                                     0.063
  ≤ 60                    698 (50.5)    480 (53.2)   218 (45.3)                 437 (50.3)      261 (50.7)                   233 (54.2)   465 (48.8)   
  \> 60                   685 (49.5)    422 (46.8)   263 (54.7)                 431 (49.7)      254 (49.7)                   197 (45.8)   488 (51.2)   
  Gender                                                             0.067                                   0.422                                     0.927
  Male                    808 (58.4)    511 (56.7)   297 (61.7)                 500 (57.6)      308 (59.8)                   252 (58.6)   536 (58.3)   
  Female                  575 (41.6)    391 (43.3)   184 (38.3)                 368 (42.4)      207 (40.2)                   178 (41.4)   397 (41.7)   
  Tumor location                                                     \< 0.001                                0.008                                     0.060
  Right-sided             324 (23.4)    185 (20.5)   139 (28.9)                 183 (21.1)      141 (27.4)                   87 (20.2)    237 (24.9)   
  Left-sided              1059 (76.6)   717 (79.5)   342 (71.1)                 685 (78.9)      374 (72.3)                   343 (79.8)   716 (75.1)   
  Histological type                                                  \< 0.001                                0.020                                     \< 0.001
  Well-differentiated     1126 (81.4)   761 (84.4)   365 (75.9)                 723 (83.3)      403 (78.3)                   376 (87.4)   750 (78.7)   
  Poorly differentiated   257 (18.6)    141 (15.6)   116 (24.1)                 145 (16.7)      112 (21.7)                   54 (12.6)    203 (21.3)   
  Tumor size                                                         \< 0.001                                \< 0.001                                  0.003
  ≤ 5 cm                  936 (67.7)    660 (73.2)   276 (57.4)                 617 (71.1)      319 (61.9)                   315 (73.3)   621 (65.2)   
  \> 5 cm                 447 (32.3)    242 (26.8)   205 (42.6)                 251 (28.9)      196 (38.1)                   115 (26.7)   332 (34.8)   
  T stage                                                            \< 0.001                                \< 0.001                                  \< 0.001
  T1                      67 (4.8)      45 (5.0)     22 (4.6)                   54 (4.9)        13 (4.8)                     38 (8.8)     29 (3.0)     
  T2                      256 (18.5)    197 (21.8)   59 (12.3)                  170 (19.9)      86 (16.7)                    104 (24.2)   152 (15.9)   
  T3                      748 (54.1)    507 (56.2)   241 (50.1)                 475 (54.7)      273 (53.0)                   232 (54.0)   516 (54.1)   
  T4                      312 (22.6)    153 (17.0)   159 (33.1)                 169 (19.5)      143 (27.8)                   56 (13.0)    256 (26.9)   
  N stage                                                            \< 0.001                                0.021                                     \< 0.001
  N0                      487 (35.2)    353 (39.1)   134 (27.9)                 325 (37.4)      162 (31.5)                   196 (45.6)   291 (30.5)   
  N1                      416 (30.1)    277 (30.7)   139 (28.9)                 261 (30.1)      155 (30.1)                   121 (28.1)   295 (31.0)   
  N2                      308 (22.3)    188 (20.8)   120 (24.9)                 190 (21.9)      118 (22.9)                   77 (17.9)    231 (24.2)   
  N3                      172 (12.4)    84 (9.3)     88 (18.3)                  92 (10.6)       80 (15.5)                    36 (8.4)     136 (14.3)   
  M stage                                                            \< 0.001                                \< 0.001                                  \< 0.001
  M0                      1115 (80.6)   774 (85.8)   341 (70.9)                 726 (83.6)      389 (75.5)                   386 (89.8)   729 (76.5)   
  M1                      268 (19.4)    128 (14.2)   140 (29.1)                 142 (16.4)      126 (24.5)                   44 (10.2)    224 (23.5)   
  TNM stage                                                          \< 0.001                                0.001                                     \< 0.001
  I                       187 (13.5)    141 (15.6)   46 (9.6)                   133 (15.3)      54 (10.5)                    92 (21.4)    95 (10.0)    
  II                      515 (37.2)    368 (40.8)   147 (30.6)                 335 (38.6)      180 (35.0)                   171 (39.8)   344 (36.1)   
  III                     413 (29.9)    265 (29.4)   148 (30.8)                 258 (29.7)      155 (30.1)                   123 (28.6)   290 (30.4)   
  IV                      268 (19.4)    128 (14.2)   140 (29.1)                 142 (16.4)      126 (24.5)                   44 (10.2)    224 (23.5)   
  Chemotherapy                                                       \< 0.001                                \< 0.001                                  \< 0.001
  No                      684 (49.5)    488 (54.1)   196 (40.7)                 472 (54.4)      212 (41.2)                   243 (56.5)   441 (46.3)   
  Yes                     699 (50.5)    414 (45.9)   285 (59.3)                 396 (45.6)      303 (58.8)                   187 (43.5)   512 (53.7)   

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.

Prognostic value of NLR, PLR, and SII
-------------------------------------

In the present study, the 5-, 10-, 15-, and 20-year OS rates were 61.2%, 45.1%, 35.6%, and 28.1%, respectively. The patients in the high NLR, PLR, and SII groups showed poorer OS compared to patients in the low NLR, PLR, and SII groups, respectively (Figure [1A](#F1){ref-type="fig"}-C). In order to identify the prognostic parameters for OS, 13 variables were included in the univariate Cox regression analysis, which showed that the NLR, PLR, SII, age, histological type, tumor invasion, lymph node involvement, distant metastasis, TNM stage, and chemotherapy were the variables that had significant impact on OS. After the exclusion of variables that showed no impact on the OS in univariate analysis, Cox multivariate regression analysis was performed, which identified SII (95%CI: 2.616-3.824), PLR (95%CI: 1.123-1.492), age (95%CI: 1.355-1.798), distant metastasis (95%CI: 1.512-2.517), and TNM stage (95%CI: 1.191-1.518) as the independent prognostic factors of OS (Table [2](#T2){ref-type="table"}).

![Kaplan-Meier curves of overall survival and disease-free survival of colorectal cancer patients based on neutrophil-lymphocyte ratio (A and D), platelet-lymphocyte ratio (B and E), and systemic immune-inflammation index (C and F).](WJG-23-6261-g001){#F1}

###### 

Univariate and multivariate Cox regression analysis of the associations between clinical parameters and overall survival in patients with colorectal cancer

                      **Univariate analysis**   **Multivariate analysis**                                                            
  ------------------- ------------------------- --------------------------- ------------- ---------- --------- ------- ------------- ----------
  Age                 22.965                    1.405                       1.223-1.614   \< 0.001   38.131    1.561   1.355-1.798   \< 0.001
  Gender              0.017                     \-                          \-            0.896                                      
  Tumor location      0.269                     \-                          \-            0.604                                      
  Histological type   22.178                    1.493                       1.264-1.764   \< 0.001                                   
  Tumor size          1.166                     \-                          \-            0.280                                      
  T stage             71.702                    1.498                       1.364-1.645   \< 0.001                                   
  N stage             113.905                   1.432                       1.340-1.529   \< 0.001                                   
  M stage             239.937                   3.415                       2.923-3.989   \< 0.001   26.390    1.951   1.512-2.517   \< 0.001
  TNM stage           207.252                   1.785                       1.650-1.932   \< 0.001   22.971    1.345   1.191-1.518   \< 0.001
  NLR status          40.824                    1.582                       1.374-1.821   \< 0.001                                   
  PLR status          23.604                    1.416                       1.231-1.649   \< 0.001   12.618    1.294   1.123-1.492   \< 0.001
  SII status          173.330                   3.529                       2.925-4.258   \< 0.001   141.427   3.163   2.616-3.824   \< 0.001
  Chemotherapy        76.931                    1.894                       1.642-2.184   \< 0.001                                   

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio.

Similarly, the 5-, 10-, 15-, and 20-year DFS rates were 56.5%, 39.1%, 31.3%, and 26.5%, respectively. The DFS rates were lower in patients with high NLR, PLR, and SII compared to those of the patients with low NLR, PLR, and SII, respectively (Figure [1D](#F1){ref-type="fig"}-F). The DFS data for the three patient groups are demonstrated in Table [3](#T3){ref-type="table"}. Univariate Cox proportional hazards regression analysis revealed that age, histological type, tumor invasion, lymph node involvement, distant metastasis, TNM stage, chemotherapy, NLR, PLR, and SII had statistically significant associations with DFS. In addition, multivariate analysis indicated that SII was a significant independent prognostic parameter for DFS, whereas PLR and NLR were not (Table [3](#T3){ref-type="table"}).

###### 

Univariate and multivariate Cox regression analysis of the associations between clinical parameters and PFS in patients with colorectal cancer

                      **Univariate analysis**   **Multivariate analysis**                                                            
  ------------------- ------------------------- --------------------------- ------------- ---------- --------- ------- ------------- ----------
  Age                 21.774                    1.373                       1.202-1.569   \< 0.001   34.479    1.499   1.310-1.716   \< 0.001
  Gender              0.144                     \-                          \-            0.705                                      
  Tumor location      0.509                     \-                          \-            0.476                                      
  Histological type   20.091                    1.447                       1.231-1.701   \< 0.001                                   
  Tumor size          1.095                     \-                          \-            0.295                                      
  T stage             59.847                    1.419                       1.299-1.550   \< 0.001                                   
  N stage             86.718                    1.354                       1.270-1.443   \< 0.001                                   
  M stage             221.926                   3.172                       2.725-3.692   \< 0.001   31.580    2.024   1.583-2.589   \< 0.001
  TNM stage           179.589                   1.673                       1.552-1.804   \< 0.001   15.414    1.255   1.121-1.406   \< 0.001
  NLR status          36.441                    1.518                       1.325-1.738   \< 0.001                                   
  PLR status          20.826                    1.369                       1.196-1.567   \< 0.001                                   
  SII status          159.123                   2.988                       2.521-3.542   \< 0.001   129.495   2.717   2.287-3.228   \< 0.001
  Chemotherapy        61.159                    1.716                       1.499-1.965   \< 0.001                                   

NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio.

The AUCs of the NLR, PLR, and SII for OS were 0.602, 0.566, and 0.707, respectively (Figure [2A](#F2){ref-type="fig"}) and the AUCs for DFS were 0.597, 0.558, and 0.701, respectively (Figure [2B](#F2){ref-type="fig"}). Hence, among the immune-inflammation indices analyzed in the present study, SII was the best predictor of long-term survival and recurrence in cases with CRC.

![Receiver operating curve analysis of overall survival (A) and disease-free survival (B). NLR: Neutrophil-lymphocyte ratio; PLR: Platelet-lymphocyte ratio; SII: Systemic immune-inflammation index.](WJG-23-6261-g002){#F2}

Prognostic value of NLR, PLR, and SII stratified according to TNM stage
-----------------------------------------------------------------------

Further subgroup analyses were performed to investigate the prognostic value of SII, NLR, and PLR in patients with CRC who were stratified according to the TNM stage. The results of the analyses showed that only SII was able to distinguish the OS and DFS for each TNM stage (Figure [3A](#F3){ref-type="fig"}-F). On the other hand, NLR could identify the survival differences between TNM stages II-IV, while PLR could only detect the prognostic differences of stage II-III cancers (Figure [4A](#F4){ref-type="fig"}-F for NLR and Figure [5A](#F5){ref-type="fig"}-F for PLR). Hence, the results indicated that only SII had prognostic significance for the CRC cases stratified according to TNM stage.

![Kaplan-Meier curves of overall survival and disease-free survival of colorectal cancer patients based on different levels of systemic immune-inflammation index. A-D: OS for cases with stages I, II, III, and IV CRC, respectively; E and F: DFS for cases with stages I, II, III, and IV CRC, respectively. OS: Overall survival; DFS: Disease-free survival; CRC: Colorectal cancer.](WJG-23-6261-g003){#F3}

![Kaplan-Meier curves of overall survival and disease-free survival of colorectal cancer patients based on different levels of neutrophil-lymphocyte ratio. A-D: OS for cases with stages I, II, III, and IV CRC, respectively; E and F: DFS for cases with stages I, II, III, and IV CRC, respectively. OS: Overall survival; DFS: Disease-free survival; CRC: Colorectal cancer; NLR: Neutrophil-lymphocyte ratio.](WJG-23-6261-g004){#F4}

![Kaplan-Meier curves of overall survival and disease-free survival of colorectal cancer patients based on different levels of platelet-lymphocyte ratio. A-D: OS for cases with stages I, II, III, and IV CRC, respectively; E-F: DFS for cases with stages I, II, III, and IV CRC, respectively. OS: Overall survival; DFS: Disease-free survival; CRC: Colorectal cancer; PLR: Platelet-lymphocyte ratio.](WJG-23-6261-g005){#F5}

DISCUSSION
==========

In the present study, we established an immune-inflammation-based prognostic index (SII) based on peripheral neutrophil, platelet, and lymphocyte counts and demonstrated that elevated SII was correlated with poor OS and recurrence in patients with CRC. In addition, SII was a superior prognostic factor for survival outcome compared to NLR and PLR.

It was recognized that inflammatory-based indices were associated with poor tumor behavior and survival outcome in various malignant solid tumors, including CRC. Several combinations such as NLR\[[@B14]\], PLR\[[@B15]\], prognostic nutritional index\[[@B16]\], Glasgow Prognostic score\[[@B17]\], and lymphocyte monocyte ratio (LMR)\[[@B18]\] showed positive correlations between elevated inflammation-based factors and poor survival outcome in patients with CRC. To our knowledge, this was the first report investigating the prognostic value of SII in patients with CRC after radical surgery. Using an integrated index based on peripheral neutrophil, platelet, and lymphocyte counts, Hu et al\[[@B12]\] found that patients having elevated preoperative SII were usually diagnosed with thrombocytosis, neutropenia, or lymphopenia. They believed that a better understanding of the roles of neutrophils, platelets, and lymphocytes in cancer development and progression would help clarify the association between SII and its clinical impact. Neutrophils do not only alter the tumor microenvironment *via* the extrinsic pathway, but they also secrete some inflammatory mediators to promote tumor cell proliferation, invasion, metastasis to lymph nodes or distant organs, and cellular senescence *via* the intrinsic pathway\[[@B19],[@B20]\]. Accumulating experimental and clinical evidence showed that platelet activation could act as chemoattractants for cancer cells, induce the formation of optimized conditions for metastatic foci, promote the epithelial to mesenchymal transition in tumor cells, and increase the level of circulating tumor cells\[[@B21],[@B22]\]. Lymphopenia was commonly accompanied by leukocytosis and thrombocytosis, which might help tumor cells to escape immune surveillance and prevent damage from the autoimmune response by cytotoxic T cells\[[@B23]\]. There was a good and a bad inflammatory reaction. In other words if the inflammation was based on the production of simply growth factors, the inflammatory reaction has a negative effect. But if the inflammatory reaction consists on neutralizing antibodies produced by activated lymph nodes, this reaction can have a positive effect. Thus, a high SII level reflected alterations in the cancer microenvironment that favor cancer initiation, progression, and metastasis.

The present study revealed interesting associations between inflammation-based indices and clinicopathological features. Consistent with the clinicopathological features associated with NLR and PLR, which are the most common indices, SII was also associated with poor histological differentiation, larger tumor size, more advanced T stage, N stage, M stage, and TNM stage, validating the above hypothesis that the elevated inflammatory response might promote tumor proliferation, progression, and metastasis.

As a simple, convenient, easily obtained, cheap, and non-invasive marker, SII was first described by Hu et al\[[@B12]\] in hepatocellular carcinoma. They concluded that preoperative SII might be related to circulating tumor cells and act as a powerful prognostic predictor in patients with hepatocellular carcinoma. Consistent with the results of previous studies, Yang et al\[[@B24]\] also reported that elevated SII with a cut-off value of 300 was negatively associated with OS in HBV-related hepatocellular carcinoma\[[@B25]\]. Moreover, SII was reported as a predictor of metastatic CRC in patients who received first-line chemotherapy with bevacizumab\[[@B26]\]. To our knowledge, the present study was the first to investigate the prognostic value of SII in CRC. Confirmed by the Kaplan-Meier analysis using the log-rank method, all the inflammation-based indices were significantly associated with OS and recurrence. However, SII was identified in Cox multivariate analysis to be a superior predictor of OS and DFS compared to other inflammation-based prognostic indices. The discriminative abilities of these three indices were further evaluated and compared; based on the AUC values obtained from ROC curves, SII was the most effective predictor of long-term survival outcome compared to NLR and PLR. The potential explanation of a better prognostic value might be that SII was more comprehensive in reflecting the status of inflammatory and immune response than the other factors.

Pathological TNM staging is presently the gold standard for predicting survival outcome and the treatment choice. However, because TNM staging was performed postoperatively, survival prediction before surgery and decision of further treatment strategies became difficult. Moreover, TNM stage can only reflect the biological behavior of the tumor. To our knowledge, prognosis was not only associated with the clinicopathological characteristics of the tumor, but also with the host inflammatory response\[[@B27]\]. SII is based on peripheral neutrophil, platelet, and lymphocyte counts, and it reflects the status of the tumor microenvironment and the preoperative host inflammatory response, serving as a complementary to the TNM stage for predicting OS. Our findings demonstrated that preoperative SII had powerful prognostic discriminative abilities in terms of each TNM subgroup compared to NLR and PLR. Therefore, using a combination of parameters that reflect both the tumor characteristics and the host systemic inflammatory status might be important for accurately predicting survival outcome in patients with CRC.

The present study had a few limitations. First, it was a retrospective, single-center study. Therefore, a large-scale prospective validation study is required to validate the results of the present study. Second, only the patients who received radical surgery were enrolled and thus, the results of the present study are not applicable in incurable patients or in those for whom the treatment was terminated because of various reasons.

In conclusion, this was the first study to demonstrate that preoperative SII is a simple and powerful prognostic indicator of OS and DFS in patients with CRC. SII might be used along with the TNM staging for individualized treatment in future clinical practice. A larger prospective study is warranted for the validation of the preliminary results obtained in the present study.

COMMENTS
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Background
----------

Recently, there were many papers describing mathematical formulas, such as neutrophil-lymphocyte ratio and platelet-lymphocyte ratio, which were considered important prognostic factors for colorectal cancer (CRC). In this article, the authors want to investigate the clinical value of systemic immune-inflammation index (SII), an integrated indicator based on peripheral lymphocyte, neutrophil, and platelet counts.

Research frontiers
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The interplay between systemic inflammation and the local immune response was recognized as the seventh hallmark of cancer, and it has been demonstrated to be involved in the initiation, development, and progression of several types of malignancies. Inflammation can produce several cytokines and growth factors which can facilitate the occurrence and development of cancer. We established a systemic inflammation parameter, SII and found that SII had better prognostic predictive abilities for overall survival and recurrence of CRC in this study.

Innovations and breakthroughs
-----------------------------

Preoperative SII based on peripheral lymphocyte, neutrophil, and platelet counts was established, and no study investigated the clinical value of SII in CRC before. We found that SII had better prognostic predicting abilities for overall survival and recurrence when compared with neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in patients with CRC. It might assist the identification of high-risk patients among patients with the same TNM stage in clinical practice.

Applications
------------

Patients with high SII showed aggressive tumor biological behavior, poor overall survival and early tumor recurrence. Hence, SII may give help to identify the high-risk patients among patients with the same TNM stage in clinical practice.

Terminology
-----------

SII is based on the peripheral lymphocyte, neutrophil, and platelet counts, and is calculated using the formula SII = (P × N)/L, where P, N, and L refer to the preoperative peripheral platelet, neutrophil, and lymphocyte counts, respectively.
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